Generic Neoral Availability

Neoral is a brand name of cyclosporine, approved by the FDA in the following formulation(s):

NEORAL (cyclosporine - capsule;oral)

  • Manufacturer: NOVARTIS
    Approval date: July 14, 1995
    Strength(s): 25MG [AB1], 100MG [RLD] [AB1]

NEORAL (cyclosporine - solution;oral)

  • Manufacturer: NOVARTIS
    Approval date: July 14, 1995
    Strength(s): 100MG/ML [RLD] [AB1]

Has a generic version of Neoral been approved?

A generic version of Neoral has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Neoral and have been approved by the FDA:

cyclosporine capsule;oral

  • Manufacturer: IVAX SUB TEVA PHARMS
    Approval date: March 29, 2005
    Strength(s): 25MG [AB1], 100MG [AB1]
  • Manufacturer: SANDOZ
    Approval date: January 13, 2000
    Strength(s): 25MG [AB1], 100MG [AB1]
  • Manufacturer: WATSON LABS INC
    Approval date: December 20, 2000
    Strength(s): 25MG [AB1], 100MG [AB1]

cyclosporine solution;oral

  • Manufacturer: ABBVIE
    Approval date: March 3, 2000
    Strength(s): 100MG/ML [AB1]
  • Manufacturer: IVAX SUB TEVA PHARMS
    Approval date: March 25, 2005
    Strength(s): 100MG/ML [AB1]
  • Manufacturer: WATSON LABS
    Approval date: December 18, 2001
    Strength(s): 100MG/ML [AB1]

GENGRAF (cyclosporine capsule;oral)

  • Manufacturer: ABBVIE
    Approval date: May 12, 2000
    Strength(s): 25MG [AB1], 100MG [AB1]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Neoral. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Soft gelatin capsule manufacture
    Patent 5,985,321
    Issued: November 16, 1999
    Inventor(s): Brox; Werner & Meinzer; Armin & Zande; Horst
    Assignee(s): Novartis AG R.P. Scherer GmbH
    Soft gelatin capsules having a capsule shell comprising gelatin, plasticizers and, if desired or required, further auxiliary agents, and a capsule filling containing a solvent including a migrateable solvent such as 1,2-propyleneglycol as a solvent in the capsule filling and in the capsule shell. The manufacture of said capsules is improved, if in the process for making the soft gelatin capsules the gelatin bands are cooled with a liquid, and preferably with water.
    Patent expiration dates:
    • September 26, 2014
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web4)